A new partnership combines AI-driven molecular discovery with industrial-scale radionuclide production to accelerate the development of precision oncology therapies.

Sanyou Biopharmaceutical Co., Ltd. and Guangzhou Baiyunshan Xihe Health Pharmaceutical Co., Ltd. formalized a strategic cooperation agreement on July 4, 2026, to advance the development of next-generation radiopharmaceuticals. According to a press release from Sanyou Biopharmaceutical, this collaboration merges advanced artificial intelligence with established nuclear medicine infrastructure to streamline the pipeline from initial molecular design to clinical application.
Sanyou Bio will deploy its proprietary AI-Super trillion antibody/molecule libraries, known as AI-STAL, alongside the Sanyou AI-Drug Accelerator to identify high-performance targeting molecules. These digital tools provide the foundational innovation required to meet the stringent precision and stability demands of modern radiotherapeutic agents, which often face significant hurdles in biological targeting and systemic clearance.
Baiyunshan Xihe contributes its extensive industrial capabilities, including the production of medical radionuclides and GMP-compliant manufacturing facilities. The company manages a specialized portfolio that includes nanobody-based radiopharmaceuticals and microsphere products, providing the necessary framework for preclinical and clinical translation within the complex regulatory environment of the Chinese healthcare market.
The agreement establishes an integrated R&D model designed to connect upstream molecular discovery with downstream industrialization. By creating this closed-loop system, the companies aim to reduce the time required to move candidate compounds from conceptual target identification to active clinical development, a process that historically suffers from fragmented workflows between research labs and manufacturing centers.
The joint effort will focus on utilizing key medical radionuclides such as Gallium-68, Zirconium-89, Copper-64, and Rhenium-186. These materials are essential for creating theranostic products that combine diagnostic imaging with therapeutic intervention in oncology, allowing clinicians to visualize and treat tumors simultaneously with high specificity.
Both firms are responding to the technical challenges inherent in radiopharmaceutical development, where the short half-life of isotopes requires rapid, precise, and stable molecular binding. By integrating AI-driven molecular design, the partners intend to optimize the druggability of these compounds, ensuring they remain effective while minimizing off-target toxicity in patients.
The current state of the Chinese nuclear medicine market is characterized by a rapid shift toward localized, high-quality production of isotopes and advanced therapeutic agents. This partnership serves as a strategic response to the rising demand for personalized cancer treatments, positioning both companies to capture significant market share as the industry matures and regulatory standards for radiopharmaceuticals continue to tighten.
Liu Hong, Chairman and General Manager of Baiyunshan Xihe, noted that the partnership leverages the company’s position as a leader in the Guangzhou nuclear medicine sector. He emphasized that the integration of Sanyou Bio’s screening technology will significantly enhance the speed and efficacy of their current theranostic pipeline, effectively bridging the gap between theoretical research and tangible clinical outcomes.
Dr. Lang Guojun, Founder and CEO of Sanyou Bio, described the move as a critical expansion of the company’s mission to simplify global drug development. He stated that the synergy between intelligent molecular design and precise radionuclide labeling offers a fundamental solution to existing bottlenecks in the nuclear medicine industry, empowering the technological upgrade of the global sector.
The collaboration reflects a broader industry trend toward horizontal integration, where technology-first firms partner with manufacturing-heavy entities to solve complex biological challenges. By combining computational power with physical production capacity, the two firms seek to establish a new benchmark for high-quality development in the Chinese radiopharmaceutical market, ensuring that innovative therapies reach patients with greater efficiency.
Stakeholders in the healthcare sector view this union as a strategic move to address the scarcity of high-performance targeting molecules. The ability to rapidly iterate on molecular targets while maintaining a clear path to clinical manufacturing provides a distinct competitive advantage in the global oncology market, where precision medicine is becoming the standard of care.
Future milestones for the partnership will include the selection of initial candidate compounds for joint development and the subsequent initiation of preclinical trials. Both organizations have committed to exploring deeper collaboration opportunities, signaling a long-term intent to influence the trajectory of upstream innovation in nuclear medicine and solidify their roles as key players in the evolving landscape of precision oncology.